

## **BioSpecifics Technologies Corp. to Present at Cowen and Company 31<sup>st</sup> Annual Health Care Conference**

LYNBROOK, NY – March 3, 2011 - BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Cowen and Company 31<sup>st</sup> Annual Health Care Conference on Monday, March 7, 2011, at 1:45pm ET at the Boston Marriott Copley Place in Boston, Massachusetts.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at [www.biospecifics.com](http://www.biospecifics.com), or you may use the link: <http://www.wsw.com/webcast/cowen3/bstc/>.

### **About BioSpecifics Technologies Corp.**

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its licensee Auxilium markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in Europe. More information about the Company may be found on its website at [www.biospecifics.com](http://www.biospecifics.com).

### **Contact:**

BioSpecifics Technologies Corp.  
Thomas L. Wegman, President  
(516) 593-7000  
[thomas\\_wegman@biospecifics.com](mailto:thomas_wegman@biospecifics.com)